> Contact
> Homepage
> Site map
> Links

About HIFU
About Ablatherm
Clinical Information
Clinical Results
  Large Cohort Studies
  Long Term Results
  PSA Stability
  Safety Results
Clinical Trials


Published Abstracts
& Articles
Video Clips
 You are here : Physicians > HIFU - Ablatherm > Clinical Results > Large Cohort Studies

Studies with large cohort of patients are available…

From 1995 to 1999, 559 patients were included in a European multi-centric study (1). Most of the patients (n=402) were T1-T2 patients treated with Ablatherm-HIFU as first choice therapy. In this T1-T2 population, negative biopsies were observed in 87.2% of the patients. At least 50% of the patients presented a nadir PSA at 0.1 or less after a complete treatment.


A special highlight on the biopsy results according to the disease related initial risk level shows that 92,1 % of the low risk patients (cancer involving less than half a lobe, PSA <10ng/ml and Gleason sum lower or equal to 6) presented negative biopsies during their overall follow-up (up to 51 months).

(1) C. Chaussy, S. Thüroff, G. Vallancien, W. Wieland, H.J. Kiel, A. Le Duc, F. Desgranchamps, J. de la Rosette, A. Gelet - HIFU for the Treatment of Localized Prostate Cancer: Efficacy Results of the European Multicentric Study - The Journal Of Urology, May 2001, Vol. 165, 5:388
® Ablatherm is aregistered trademark of EDAP.
© Copyright 2002 EDAP. All rights reserved.